{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:08:24Z","timestamp":1782785304343,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.msard.2021.103229","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T16:33:38Z","timestamp":1630168418000},"page":"103229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses"],"prefix":"10.1016","volume":"56","author":[{"given":"Samantha E.","family":"Epstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaho","family":"Onomichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Langston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Yeshokumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana Katz","family":"Sand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Klineova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Lublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiersten","family":"Dykstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongqi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"De Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libby","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Farber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy S.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103229_bib0002","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.103229_bib0003","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103229_bib0004","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103229_bib0005","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00415-018-9160-9","article-title":"Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults","volume":"266","author":"Cobo-Calvo","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103229_bib0006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2021.103229_bib0007","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/dmcn.13703","article-title":"Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes","volume":"60","author":"Duignan","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.msard.2021.103229_bib0008","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.25957","article-title":"Silent new brain MRI lesions in children with MOG-antibody associated disease","volume":"89","author":"Fadda","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103229_bib0009","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103229_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103229_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0037-1604404","article-title":"MOG spectrum disorders and role of MOG-antibodies in clinical practice","volume":"49","author":"Hennes","year":"2018","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.msard.2021.103229_bib0012","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103229_bib0013","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2021.103229_bib0014","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J .Neuroinflammation"},{"key":"10.1016\/j.msard.2021.103229_bib0015","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103229_bib0016","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103229_bib0017","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1177\/1352458518811597","article-title":"Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis","volume":"25","author":"Oliveira","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103229_bib0018","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2021.103229_bib0019","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2021.103229_bib0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2021.103229_bib0021","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1016\/j.vaccine.2007.04.060","article-title":"Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Sejvar","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2021.103229_bib0022","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1212\/01.wnl.0000259404.51352.7f","article-title":"Acute disseminated encephalomyelitis","volume":"68","author":"Tenembaum","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103229_bib0001","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1212\/WNL.59.4.499","article-title":"Proposed diagnostic criteria and nosology of acute transverse myelitis","volume":"59","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103229_bib0023","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103229_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418762083","article-title":"Defining distinct features of anti-MOG antibody associated central nervous system demyelination","volume":"11","author":"Weber","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103229_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103229_bib0026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103229_bib0027","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103229_bib0028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J. Neuroimmunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482100496X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482100496X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:57:43Z","timestamp":1761901063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482100496X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":28,"alternative-id":["S221103482100496X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103229","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103229"}}